The presence of Pars Isotope in the Annual EANM Congress10th September 2023The presence of Pars Isotope in the Annual EANM Congress Pars…
Pictures and news reports from the Pars Isotope booth at the conference of South African Society of Nuclear Medicine (SASNM)2nd September 2023Pictures and news reports from the Pars Isotope booth at the…
Presence of Pars Isotope Co. at the SASNM congress in South Africa23rd August 2023Presence of Pars Isotope Co. at the SASNM congress in South…
The new phantom manufactured by Pars Isotope Co. received approval from Imam Khomeini Hospital in Tehran.19th July 2023The new phantom manufactured by Pars Isotope Co. received approval from…
Obtaining a bilingual GMP certificate from Iran Food and Drug Administration (IFDA) for the production lines of FDG radiopharmaceutical and the Pars-GalluGEN generator18th June 2023Obtaining a bilingual GMP certificate from Iran Food and Drug Administration…
Presence of Pars Isotope in the 6th International Cancer Congress8th May 2023Presence of Pars Isotope in the 6th International Cancer Congress Pars…
The presence of Pars Isotope Co. in International Symposium on Trends in Radiopharmaceuticals in Austria19th April 2023The presence of Pars Isotope Co. in International Symposium on Trends…
The presence of Pars Isotope in the international health exhibition of Venezuela (FISVEN)1st April 2023The presence of Pars Isotope in the international health exhibition of…
The Administrator of Drug and Controlled Substances Affairs of the Food and Drug Organization Visited Pars Isotope Company.11th March 2023The Administrator of Drug and Controlled Substances Affairs of the Food…
Utilizing radiopharmaceuticals made by Pars Isotope Co. for the feasibility and investigation of the therapeutic potential of (Ga-68/Lu-177)-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.1st March 2023Utilizing radiopharmaceuticals made by Pars Isotope Co. for the feasibility and…